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http://dxObjective: Differences in clinical presentation between patients with tricuspid aortic valves (TAVs) or bicuspid
aortic valves (BAVs) and aortic valve disease are evident. Whether these differences can be attributed to
differences in cardiovascular risks remains uncertain.
Methods: Patient characteristics, echocardiographic findings, medical history, medication, and laboratory
findings were evaluated in 702 patients with aortic valve and/or ascending aortic pathology; 202 also had
concomitant coronary artery disease.
Results: A BAV was commonly found in patients with isolated valve disease (BAV 47%, TAV 53%) and
frequently associated with ascending aortic dilatation (BAV 80%, TAV 20%). In patients with coronary artery
disease, a TAV was commonly found (TAV 84%, BAV 16%). The combination of ascending aortic dilatation
and coronary artery disease was markedly rare regardless of valve morphology (TAV, 7 out of 38; BAV, 6 out
of 127). The distribution of valve pathology and clinical parameters was similar in patients with TAV and
BAV with coronary artery disease (P  .12). Without coronary artery disease, parameters associated with
cardiovascular risks were more often seen in patients with TAV than in patients with BAV (P  .0001).
Conclusions: Coronary artery disease is uncommon in surgical patients with BAV, but it is associated with TAV,
advanced age, andmale gender. Coronary artery disease and ascending aortic dilatation rarely coexist, regardless
of valve phenotype. Differences in the prevalence of coronary artery disease or ascending aortic dilatation
between patients with TAVand BAVare not explained by differences in cardiovascular risks or the distribution
of valve pathology. (J Thorac Cardiovasc Surg 2014;148:2973-80)DSupplemental material is available online.A
CA bicuspid aortic valve (BAV) is the most common cardiac
malformation, with an estimated prevalence of 0.5% to 2%1
and a male to female ratio of 3:1.2 It is believed to be auto-
somal dominantly inherited with reduced penetrance3 and
is associated with other congenital cardiovascular lesions.4
Typically a BAV fails earlier in life and BAV patients are
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The Journal of Thoracic and Caraortic valves (TAV), when the surgical correction of aortic
valve pathology is indicated.5,6 In addition, the BAV
population is reported to have a calculated age-adjusted
relative risk of aneurysm formation of 86.2 and aortic
dissection of 8.4 compared with the general population.7
The disproportion of aortic aneurysms and aortic dissection
rates may indicate that factors other than aorta size
contribute to the incidence of aortic dissection in patients
with BAV.7
The underlying pathologic mechanisms of aneurysm
formation in patients with TAVand BAVare still not known.
There are reports of a genetic predisposition for a weakened
aortic wall in patients with BAV8-11 but also of
hemodynamic influences on the aortic wall caused by the
malformed valve possibly leading to aortic dilatation.12,13
Moreover, aneurysm formation in patients with TAV, but
not BAV, is associated with an immune response and
inflammation of the intima/media region of the aortic
wall.14 It is well known that atherosclerosis and inflamma-
tion play important roles in the pathogenesis of coronary
artery disease15 as well as in the formation of aortic valve
stenosis.16
Differences in clinical presentation between patients with
BAVor TAVand aortic valve disease are evident.2,17Whether
these differences can be attributed to differences in
cardiovascular risks remains uncertain. We evaluateddiovascular Surgery c Volume 148, Number 6 2973
Abbreviations and Acronyms
ASAP ¼ Advanced Study of Aortic Pathology
BAV ¼ bicuspid aortic valve
TAV ¼ tricuspid aortic valve
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cal history, medication, and laboratory findings in patients
undergoing aortic valve surgery with or without concurrent
replacement of the ascending aorta and/or concurrent
coronary artery bypass grafting.METHODS
The study population consisted of a total of 702 patients undergoing
cardiac surgery between February 2007 and February 2012.
A total of 500 consecutive patients who underwent surgery because of
aortic valve and/or ascending aortic pathology within the setting of the
Advanced Study of Aortic Pathology (ASAP), a prospective single center
study,5 were included. Patients with coronary artery disease, defined as
significant stenosis on coronary angiogram, were not included in the
ASAP study. Patients were stratified according to valve morphology
(TAV/BAV) and ascending aortic morphology (nondilatated or dilatated
ascending aorta) based on intraoperative transesophageal echocardiogra-
phy examination and valve inspection by the surgeon. The definitions of
valve pathology and ascending aortic pathology, as well as how the
echocardiographic measurements were obtained, have been described in
detail previously.5 In addition, 202 patients, who were not included in
the ASAP study but who had undergone aortic valve surgery during the
same time period as patients of the ASAP study, with or without concurrent
replacement of the aortic root and/or ascending aorta, who had undergone
coronary artery bypass grafting, were included; all medical records were
reviewed retrospectively. Patients were stratified according to valve
morphology (based on the surgeon’s inspection of the valve) and ascending
aortic morphology (based on whether the aortic root and/or the ascending
aorta was surgically replaced). Measurements of the aortic root and
ascending aorta were obtained from preoperative computed tomography
examinations. If not available, measurements from the preoperative
aortogram or from the preoperative transthoracic echocardiography
examination were used. Information on current and previous cardiovascu-
lar disease in patients and close relatives, as well as ongoing medication
and laboratory findings at the time of surgery were prospectively registered
(n ¼ 500) and retrospectively reviewed (n ¼ 202). For a complete list of
variables and parameters analyzed refer to Table E1.
The study was approved by the regional human research ethics commit-
tee and informed consent was obtained from all patients.
Patients with unicuspid aortic valves (n¼ 15), and thosewho underwent
isolated ascending aortic replacement (n ¼ 40), were not included in the
between-group comparisons. Fifteen patients did not undergo preoperative
transthoracic echocardiography within the setting of the study due to
logistic reasons. In addition, 17 patients who did not meet the criteria of
aortic valve stenosis or regurgitation according to the definitions of the
study protocol were excluded from the analyses regarding valve pathology.
Statistical Analyses
Categorical data were summarized using frequency counts and
percentages. Continuous data were presented as means  standard
deviation or as median and interquartile range (P25-P75). The Mann-
WhitneyU test and the t test for independent samples were used to compare
different subgroups for continuous variables; the c2 test and Fisher exact
test were used for categorical variables. To analyze the effect of isolated2974 The Journal of Thoracic and Cardiovascular Survalve pathology/combined valve and aortic pathology when controlling
for valve stenosis/valve regurgitation, 2-way factorial analysis of variance
was used for continuous variables and logistic regression analysis was used
for dichotomous variables. In the case of a significant interaction, simple
main effects tests were examined; that is, effects of 1 factor holding the
other factor fixed. The distribution of some variables was positively
skewed; therefore, before the formal parametric analyses, the variables
were log-transformed. Analysis of covariance and logistic regression
analysis were used to adjust for age. Software used were Statistica (version
10.0, StatSoft, Inc. Tulsa Okla) and SAS (system 9.1, SAS Institute Inc,
Cary, NC).RESULTS
Of 500 patients without coronary artery disease, 42%
had a TAVand 55% had a BAV (3% had a unicuspid aortic
valve); 60% had isolated aortic valve pathology and 32%
had concomitant ascending aortic dilatation (8% had
isolated aortic dilatation); and 80% of patients with
dilatated aortas had a BAV. The distribution of aortic valve
pathology (stenosis/regurgitation) did not differ between
TAV and BAV patients with nondilatated aortas (P ¼ .89).
With concomitant ascending aortic pathology, valve
regurgitation was the most frequent valve pathology in
patients with TAV, whereas valve stenosis was more
common in patients with BAV (P<.001) (Table 1).
Out of 202 patients with coronary artery disease, 84%
had TAVand 16% had BAV; 94% had isolated aortic valve
pathology and 6% had concomitant ascending aortic
dilatation. The distribution of valve pathology, predomi-
nantly valve stenosis, did not differ between TAV and
BAV patients with coronary artery disease and nondilatated
aortas (P ¼ .13) (Table 1). When the aorta was dilatated
coronary artery disease was uncommon in both patients
with TAV and BAV (TAV, 7 out of 38; BAV, 6 out of 127).
A TAV, isolated valve pathology, and coronary artery
disease were all associated with more advanced age
(approximately 7 years). When the aorta was dilatated, no
age differences were observed between the groups,
regardless of valve morphology or presence of coronary
artery disease (Tables 2-4).
Isolated valve pathology in combination with coronary
artery disease was associated with male gender, as was
ascending aortic dilatation in patients with TAV without
coronary artery disease. There was no difference in gender
distribution between patients with TAVand BAV, regardless
of valve pathology, presence of aortic pathology, or
presence of coronary artery disease (Tables 2-4).
Patient characteristics are given in Table 1 and the
distribution of valve morphology in relation to valve
pathology, aortic pathology, and coronary artery disease
are shown in Figure 1.Echocardiographic Findings
In both patients with TAV and BAV, aortic valve peak
gradient, mean gradient, and valve area differed betweengery c December 2014
TABLE 1. Patient characteristics and echocardiographic findings
Characteristic
No CAD (n ¼ 445) CAD (n ¼ 202)
AV (n ¼ 293) AV þ AA (n ¼ 152) AV (n ¼ 189) AV þ AA (n ¼ 13)
TAV
(n ¼ 155)
BAV
(n ¼ 138)
TAV
(n ¼ 31)
BAV
(n ¼ 121)
TAV
(n ¼ 162)
BAV
(n ¼ 27)
TAV
(n ¼ 7)
BAV
(n ¼ 6)
Age (y) 71  9 60  13 64  12 61  11 74  8 67  7 67  5 64  6
Male/female gender 92/63 93/45 25/6 93/28 124/38 24/3 7/0 5/1
BSA (m2) 1.94  0.2 1.94  0.2 2.03  0.2 2.00  0.2 1.98  0.2 2.02  0.2 2.06  0.2 1.95  0.3
SAP (mm Hg) 146  22 142  20 145  19 139  19 143  21 142  14 151  23 142  20
DAP (mm Hg) 78  16 80  12 73  1 83  12 76  10 80  11 77  12 76  11
AVPG (mm Hg) 68 (43) 74 (35) 12 (4) 61 (57) 75 (27) 74 (30) 76 (11) 64 (29)
AVMG (mm Hg) 46 (30) 46 (21) 6 (2) 39 (38) 46 (18) 46 (12) 40 (9) 41 (14)
AVA (cm2) 0.8 (0.6) 0.8 (0.5) 3.1 (1.6) 1.0 (1.1) 0.8 (0.3) 0.8 (0.4) — —
LVEDD (mm) 48 (10) 49 (11) 59 (8) 52 (10) 50 (12) 49 (8) 57 (4) 54 (32)
LVESD (mm) 32 (9.5) 34 (11) 41 (8) 35 (10) 46 (13) 33 (23) 43 (5) 31 (61)
EF (%) 60 (10) 60 (10) 56 (8) 60 (8) 51 (6) 51 (10) 61 (20) 51 (4)
Aorta (mm) 33  5 34  4 51  8 46  6 35  6 39  5 54  10 53  5
AS 110 (71) 101 (73) 2 (6) 74 (61) 135 (83) 27 (100) 2 (29) 3 (50)
AR 35 (23) 30 (22) 27 (87) 40 (33) 21 (13) 0 5 (71) 3 (50)
Values are given as mean standard deviation, median (interquartile range) (echocardiographic parameters), or frequency (%). CAD, Coronary artery disease; AV, isolated aortic
valve pathology; AA, dilatated ascending aorta; TAV, tricuspid aortic valve; BAV, bicuspid aortic valve; BSA, body surface area; SAP, systolic arterial pressure; DAP, diastolic
arterial pressure; AVPG, aortic valve peak gradient; AVMG, aortic valve mean gradient; AVA, aortic valve area; LVEDD, left ventricular end-diastolic diameter; LVESD, left
ventricular end-systolic diameter; EF, ejection fraction; AS, aortic valve stenosis; AR, aortic valve regurgitation.
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concomitant aortic pathology. It also differed between
patients with TAV and BAV with dilatated aortas. These
differences were related to the distribution of valve
pathology in the groups (Tables 1-4), as were the
differences in left ventricular diameter in the TAV group
with no coronary artery disease (Table 2), and between
patients with TAV and BAV with dilatated aortas (Table
4). In patients with TAV with combined valve pathology
and coronary artery disease, aortic valve peak gradient
was higher and aortic valve area smaller compared with
patients with TAV with isolated valve disease. This was
related to age. Thus, patients with TAVwith coronary artery
disease were older and therefore had more severe aortic
stenosis than patients with TAV without coronary artery
disease (Table 2).
A lower ejection fraction and a larger ascending aortic
diameter were both associated with coronary artery disease
in patients with TAV and patients with BAV with isolated
valve pathology, as well as in patients with BAV with
concomitant aortic dilatation (Tables 1-3). For patients
with coronary artery disease, patients with BAV with
isolated valve pathology had larger ascending aortas than
the corresponding group of patients with TAV. For
patients without coronary artery disease, patients with
TAV with dilatated aortas had larger ascending aortas than
the corresponding group of patients with BAV (Table 4).Medical History
In general, and apparent in both patients with TAV and
BAV, isolated valve pathology and coronary artery diseaseThe Journal of Thoracic and Carwere associated with a higher prevalence of comorbid
conditions and of relatives with cardiovascular disease.
This was also true for patients with TAV with isolated valve
pathology and no coronary artery disease. Arterial
hypertension and a history of stroke were more common
in the TAV group than in the BAV group (Tables 2-4). For
a complete list of parameters analyzed refer to Table E1.
Medical Treatment
A TAV, isolated valve pathology, and coronary artery
disease were associated with ongoing pharmacologic
treatment of cardiovascular disease (Tables 2-4). For a
complete list of analyzed parameters refer to Table E1.
Laboratory Findings
Coronary artery disease, and thereby advanced age, was
associated with higher levels of creatinine and C-reactive
protein in patients with BAV with isolated valve pathology
(Table 3). Patients with TAV without coronary artery
disease had higher levels of creatinine and C-reactive
protein than patients with BAV, regardless of valve and
aortic pathology (Table 4). For a complete list of variables
analyzed refer to Table E1.
DISCUSSION
Our study demonstrates that a BAV was more common
than a TAV in patients without coronary artery disease
(P< .001), whereas a TAV was markedly more common
in patients with coronary artery disease (P< .001); 80%
of patients with combined valve and aortic pathology but
no coronary artery disease had a BAV; patients with aorticdiovascular Surgery c Volume 148, Number 6 2975
TABLE 2. Clinical parameters and variables in relation to valve, aortic, and coronary artery pathology in patients with tricuspid aortic valves
(TAVs)
Parameter/variable AV (n ¼ 155) AV þ AA (n ¼ 31) P value
TAV patients without CAD
Age (y) 71  9 64  12 .001
Male/female gender 92/63 25/6 .02
Body surface area (m2) 1.94  0.2 2.03  0.2 .02
Diastolic blood pressure (mm Hg) 78  16 73  1 .02
Aortic valve peak gradient (mm Hg) 68 (43) 12 (4) <.001
Aortic valve mean gradient (mm Hg) 46 (30) 6 (2) <.001
Aortic valve area (cm2) 0.8 (0.5) 3.1 (1.6) <.001
LV end-diastolic diameter (mm) 48 (10) 59 (8) <.001
LV end-systolic diameter (mm) 32 (9.5) 41 (8) <.001
Diabetes* 22 (14) 0 .01
Relativey with VOC 24 (16) 1 (3) .04
Calcium inhibitor 36 (23) 2 (7) .03
AV (n ¼ 162) AV þ AA (n ¼ 7)
TAV patients with CAD
Age (y) 74  8 67  5 .01
Relativey with stroke 19 (13) 4 (57) .01
ACE inhibitor 46 (28) 5 (71) .03
No CAD (n ¼ 155) CAD (n ¼ 162)
TAV patients with isolated valve pathology
Age (y) 71  9 74  8 .03
Male/female gender 92/63 124/38 <.001
Aortic valve peak gradient (mm Hg) 68 (43) 75 (27) .04
Aortic valve area (cm2) 0.8 (0.6) 0.8 (0.3) .01
LV end-systolic diameter (mm) 32 (9.5) 46 (13) .004
Ejection fraction (%) 60 (10) 51 (6) <.001
Ascending aortic diameter (mm) 33  5 35  6 .01
Hypertension* 100 (65) 143 (88) <.001
Relative with sudden death 12 (8) 39 (26) <.001
Beta blocker 74 (48) 108 (67) <.001
Acetylsalicylic acid 69 (45) 110 (68) <.001
Lipid-lowering agent 79 (51) 127 (78) <.001
Insulin 3 (2) 14 (9) <.001
Long-acting nitrate 7 (5) 34 (21) <.001
No CAD (n ¼ 31) CAD (n ¼ 7)
TAV patients with concomitant valve and aortic pathology
Aortic valve peak gradient (mm Hg) 12 (4) 76 (11) .02
Aortic valve mean gradient (mm Hg) 6 (2) 40 (9) .02
Relativey with sudden death 2 (7) 3 (43) .04
Relativey with stroke 4 (13) 4 (57) .02
Values are given as mean  standard deviation, median (interquartile range) (echocardiographic parameters), or frequency (%). For a complete list of variables and parameters
analyzed refer to Table E1. AV, Isolated aortic valve pathology; AA, dilatated ascending aorta;CAD, coronary artery disease; LV, left ventricular;VOC, valvular heart disease;ACE,
angiotensin converting enzyme; TAV, tricuspid aortic valve. *As defined by ongoing medical treatment. yParent or sibling with diagnosis before age 65 years.
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disease were rarely subjected to ascending aortic replace-
ment (with coronary artery disease 6%, without 32%;
P<.001); all patients with BAV and 83% of patients with
TAV with coronary artery disease who underwent isolated
aortic valve surgery had aortic valve stenosis; coronary
artery disease was associated with TAV, advanced age,
and male gender; and patients with TAV were older than2976 The Journal of Thoracic and Cardiovascular Surpatients with BAV regardless of concomitant coronary
artery disease.
The finding that patients with BAV rarely had coronary
artery disease whereas the condition was associated with
TAV, advanced age, and male gender is in agreement
with previous work.2,18 However, the difference in the
frequency of coronary artery disease between TAV and
BAV patients was greater in our study (TAV 86% vs BAVgery c December 2014
TABLE 3. Clinical parameters and variables in relation to valve, aortic, and coronary artery pathology in patients with bicuspid aortic valves
(BAVs)
AV (n ¼ 138) AV þ AA (n ¼ 121) P value
BAV patients without CAD
Body surface area (m2) 1.94  0.2 2.00  0.2 .03
Aortic valve peak gradient (mm Hg) 74 (35) 61 (57) .005
Aortic valve mean gradient (mm Hg) 46 (21) 39 (38) .01
Aortic valve area (cm2) 0.8 (0.5) 1.0 (1.1) .003
AV (n ¼ 27) AV þ AA (n ¼ 6)
BAV patients with CAD
Lipid-lowering agent 21 (81) 1 (20) .02
No CAD (n ¼ 138) CAD (n ¼ 27)
BAV patients with isolated valve pathology
Age (y) 60  13 67  7 .002
Male/female gender 93/45 24/3 .02
Ejection fraction (%) 60 (10) 51 (10) .003
Ascending aortic diameter (mm) 34  4 39  5 <.001
Hypertension* 66 (48) 23 (85) <.001
Relative with sudden death 18 (14) 7 (32) .04
Beta blocker 56 (41) 19 (73) .003
Acetylsalicylic acid 42 (31) 21 (81) <.001
Lipid-lowering agent 48 (35) 21 (81) <.001
Thiazide diuretics 12 (8) 7 (27) .02
Long-acting nitrate 2 (1) 3 (12) .03
Creatininey (mmol/L) 78 (22) 84 (22) .03
C-reactive proteinz (mg/L) 1 (2) 3 (3) .007
No CAD (n ¼ 121) CAD (n ¼ 6)
BAV patients with concomitant valve and aortic pathology
Ejection fraction (%) 60 (8) 51 (4) .02
Ascending aortic diameter (mm) 46  6 53  5 .02
Acetylsalicylic acid 25 (21) 4 (80) .01
Other antiplatelet agent 0 1 (20) .04
Values are given as mean  standard deviation, median (interquartile range) (echocardiographic parameters), or frequency (%). For a complete list of variables and parameters
analyzed refer to Table E1. CAD, Coronary artery disease; AV, isolated aortic valve pathology; AA, dilatated ascending aorta; BAV, bicuspid aortic valve. *As defined by ongoing
medical treatment. yReference values: creatinine<90 mmol/L. zReference values: C-reactive protein<3 mg/L.
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artery disease, apparent in both patients with TAV and
BAV, had a higher prevalence of factors associated with
cardiovascular risk, manifest cardiovascular disease, and
comorbid conditions at the time of surgery (TAV:
advanced age, male gender, more severe valve stenosis,
larger ventricular dimensions, and lower ejection fraction
and TAV and BAV: larger ascending aorta, arterial
hypertension, relatives who died suddenly, and ongoing
pharmacologic treatment of cardiovascular disease).
Previous reports on age, coronary artery disease, and
concomitant coronary artery bypass grafting show these
as predictors of mortality in patients undergoing aortic
valve surgery, although the distinction between TAV and
BAV is not made.19 In our study, combined valve and
coronary artery pathology was predominantly found in
patients with TAV. Thus, valve morphology (TAVor BAV)
may be associated with differences in outcome in patients
undergoing isolated valve surgery versus valve surgeryThe Journal of Thoracic and Carwith concurrent coronary artery bypass grafting. Roberts
and colleagues18 reported no difference in long-term
survival in patients undergoing aortic valve replacement
with or without concurrent coronary artery bypass grafting,
but found a greater probability of survival in patients with
uni- or bicuspid aortic valves than in patients with TAV.
Subsequently, it was concluded that valve morphology,
but not concomitant coronary artery bypass grafting,
affected the probability of survival.18 Beach and
colleagues20 also reported on the lack of effects of coronary
artery disease on survival in patients undergoing aortic
valve replacement with or without intervention for
concomitant coronary artery disease. In our study medical
history, medication, and laboratory findings did not widely
differ between patients with TAV and BAV with coronary
artery disease. The distribution of valve pathology was
also similar in the groups where valve stenosis was
predominant, regardless of valve morphology or presence
of coronary artery disease. By contrast, patients with TAVdiovascular Surgery c Volume 148, Number 6 2977
TABLE 4. Comparison of clinical parameters and variables in relation to valve, aortic, and coronary artery pathology, between patients with
tricuspid aortic valves (TAVs) and bicuspid aortic valves (BAVs)
TAV (n ¼ 155) BAV (n ¼ 138) P value
Patients with isolated valve pathology without CAD
Age (y) 71  9 60  13 <.001
Acetylsalicylic acid 69 (45) 42 (31) .02
Lipid-lowering agent 79 (51) 48 (35) .009
Calcium inhibitor 36 (23) 17 (13) .02
Thiazide diuretics 36 (23) 12 (8) .001
Creatininey (mmol/L) 82 (22) 78 (22) .02
C-reactive proteinz (mg/L) 2 (3) 1 (2) .01
Hypertension* 100 (65) 66 (48) .005
Previous stroke 24 (15) 9 (7) .02
TAV (n ¼ 162) BAV (n ¼ 27)
Patients with isolated valve pathology and CAD
Age (y) 74  8 67  7 <.001
Anticoagulant 32 (20) 0 .009
Ascending aortic diameter (mm) 35  6 39  5 .007
TAV (n ¼ 31) BAV (n ¼ 121)
Patients with concomitant valve and aortic pathology without CAD
Diastolic blood pressure (mm Hg) 73  1 83  12 <.001
Other platelet agent 2 (1) 0 .04
Creatininey (mmol/L) 90 (21) 80 (16) .04
C-reactive proteinz (mg/L) 2 (3) 1 (2) .008
Aortic valve peak gradient (mm Hg) 12 (4) 61 (57) <.001
Aortic valve mean gradient (mm Hg) 6 (2) 39 (38) <.001
Aortic valve area (cm2) 3.1 (1.6) 1.0 (1.1) <.001
LV end-diastolic diameter (mm) 59 (8) 52 (10) <.001
LV end-systolic diameter (mm) 41 (8) 35 (10) <.001
Ascending aortic diameter (mm) 51  8 46  6 <.001
Values are given as mean  standard deviation, median (interquartile range) (echocardiographic parameters), or frequency (%). CAD, Coronary artery disease; LV, left
ventricular; TAV, tricuspid aortic valve; BAV, bicuspid aortic valve. *As defined by ongoing medical treatment. yReference value: creatinine<90 mmol/L. zReference value:
C-reactive protein<3 mg/L.
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Dwith isolated valve pathology and no coronary artery
disease were older, experienced a higher incidence of
arterial hypertension, a history of stroke, ongoing medical
treatment for cardiovascular disease, and higher creatinineFIGURE 1. Distribution of valve morphology in relation to valve pathology, a
TAV, tricuspid aortic valve; AV, isolated aortic valve pathology; AA, dilatated as
2978 The Journal of Thoracic and Cardiovascular Surlevels than the corresponding group of patients with BAV.
These findings suggest that valve morphology may
constitute a higher risk of mortality in patients undergoing
cardiac surgery, which is likely due to the more pronouncedortic morphology, and coronary artery disease. BAV, Bicuspid aortic valve;
cending aorta; CAD, coronary artery disease.
gery c December 2014
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even without manifest coronary artery disease.20 In
agreement with these findings, in our study the relative
distribution of BAV decreased substantially in the presence
of coronary artery disease.
The pathogenesis of aneurysm formation of the
ascending, descending, and abdominal aorta differs.21,22
Aneurysm formation is associated with degeneration of
the media of the aortic wall.8,21 On a progressive scale
(ascending < descending < abdominal) it is associated
with atherosclerosis and inflammation.23,24 Moreover,
aneurysm formation of the ascending aorta in patients
with TAV (but not BAV) is associated with inflammation
and immune responses.10,14 Atherosclerosis and inflam-
mation are important factors in the development of valve
stenosis and coronary artery disease15,16 and coronary
artery disease is a common finding in patients undergoing
endovascular or surgical repair of descending,
thoracoabdominal, or abdominal aortic aneurysms.25,26
Patients with TAV with dilatated aortas very rarely had
aortic valve stenosis. In addition, the combination of valve
pathology, coronary artery disease, and ascending aortic
dilatation was markedly rare. Thus, valve stenosis, with or
without coronary artery disease, was common in patients
with TAV when the aorta was not dilatated, but uncommon
when the aorta was dilatated. Despite the association of
inflammation and aneurysm formation in patients with
TAV, the combination of valve stenosis, coronary artery
disease, and aortic dilatation was rare in patients with
TAV, as well as in patients with BAV. BAV is frequently
associated with ascending aortic dilatation, which in
turn is rarely associated with coronary artery disease.
Thus, valve morphology may have an influence on the
development of coronary artery disease.
These findings may serve as grounds for choosing a less
invasive method of preoperative examination of the coro-
nary arteries (ie, computed tomography angiogram instead
of coronary angiogram) in patients with BAV without a
history of angina, as well as in patients scheduled for
ascending aortic surgery regardless of valve morphology.
Study Limitations
The study population consisted of surgical patients only;
therefore, the results may not be applicable to individuals
with TAV or BAV without indications for surgical interven-
tion. The mix of prospective and retrospective data is not
optimal and the retrospective cohort (n ¼ 202) contains
more missing values than the prospective cohort (n ¼ 500).
However, in the prospective cohort missing values were
rare and the study was a single center study with a limited
number of surgeons involved. This enabled uniformity in
the diagnosis, surgical procedures, and data collecting.
Moreover, statistical analyses were performed by an external
statistician and the results were considered valid.The Journal of Thoracic and CarCONCLUSIONS
Coronary artery disease is uncommon in BAV disease but
is associated with TAV disease, advanced age, and male
gender. Ascending aortic dilatation is predominantly found
in BAV disease. Coronary artery disease and ascending
aortic dilatation rarely coexist regardless of TAV or BAV.
Differences in the prevalence of coronary artery disease
or ascending aortic dilatation between TAV and BAV
patients are not explained by differences in risk factors
for cardiovascular disease or distribution of valve
pathology. Possible beneficial effects of BAV morphology
in cardiovascular disease need to be further evaluated.
The authors thank Elisabeth Berg, Medical Statistics Unit,
Department of Learning, Informatics, Management, and Ethics,
Karolinska Institutet, for her assistance in performing the
statistical analyses.References
1. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic
valve is heritable. J Am Coll Cardiol. 2004;44:138-43.
2. Bauer M, Bauer U, Siniawski H, Hetzer R. Differences in clinical manifestations
in patients with bicuspid and tricuspid aortic valves undergoing surgery of the
aortic valve and/or ascending aorta. Thorac Cardiovasc Surg. 2007;55:485-90.
3. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency
of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol.
1997;30:1809-12.
4. Roberts WC, Vowels TJ, Ko JM. Natural history of adults with congenitally
malformed aortic valves (unicuspid or bicuspid). Medicine (Baltimore). 2012;
91:287-308.
5. Jackson V, Petrini J, Caidahl K, Eriksson MJ, Liska J, Eriksson P, et al. Bicuspid
aortic valve leaflet morphology in relation to aortic root morphology: a study of
300 patients undergoing open-heart surgery. Eur J Cardiothorac Surg. 2011;40:
e118-24.
6. Collins MJ, Butany J, Borger MA, Strauss BH, David TE. Implications of a
congenitally abnormal valve: a study of 1025 consecutively excised aortic
valves. J Clin Pathol. 2008;61:530-6.
7. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM,
et al. Incidence of aortic complications in patients with bicuspid aortic valves.
JAMA. 2011;306:1104-12.
8. Fedak PW, de Sa MP, Verma S, Nili N, Kazemian P, Butany J, et al. Vascular
matrix remodeling in patients with bicuspid aortic valve malformations:
implications for aortic dilatation. J Thorac Cardiovasc Surg. 2003;126:797-806.
9. Pepe G, Nistri S, Giusti B, Sticchi E, AttanasioM, Porciani C, et al. Identification
of fibrillin 1 gene mutations in patients with bicuspid aortic valve (BAV) without
Marfan syndrome. BMC Med Genet. 2014;15:23.
10. Grewal N, Gittenberger-de Groot AC, Poelmann RE, Klautz RJ, Lindeman JH,
Goumans MJ, et al. Ascending aorta dilation in association with bicuspid aortic
valve: a maturation defect of the aortic wall. J Thorac Cardiovasc Surg. January
25, 2014 [Epub ahead of print].
11. McKellar SH, Tester DJ, Yagubyan M, Majumdar R, Ackerman MJ,
Sundt TM 3rd. Novel notch1 mutations in patients with bicuspid aortic valve dis-
ease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007;134:290-6.
12. Mahadevia R, Barker AJ, Schnell S, Entezari P, Kansal P, Fedak PW, et al.
Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow
patterns, wall shear stress, and expression of aortopathy. Circulation. 2014;129:
673-82.
13. Della Corte A, Bancone C, Conti CA, Votta E, Redaelli A, Del Viscovo L, et al.
Restricted cusp motion in right-left type of bicuspid aortic valves: a new risk
marker for aortopathy. J Thorac Cardiovasc Surg. 2012;144:360-9.
14. Folkersen L, Wagsater D, Paloschi V, Jackson V, Petrini J, Kurtovic S, et al.
Unraveling the divergent gene expression profiles in bicuspid and tricuspid aortic
valve patients with thoracic aortic dilatation - the ASAP study. Mol Med. 2011;
17:1365-73.
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl
J Med. 2005;352:1685-95.diovascular Surgery c Volume 148, Number 6 2979
Acquired Cardiovascular Disease Jackson et al
A
C
D16. Ngo DT, Sverdlov AL, Horowitz JD. Prevention of aortic valve stenosis:
a realistic therapeutic target? Pharmacol Ther. 2012;135:78-93.
17. Jackson V, Olsson C, Eriksson P, Franco-Cereceda A. Aortic dimensions in
patients with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg.
2013;146:605-10.
18. Roberts WC, Roberts CC, Vowels TJ, Ko JM, Filardo G, Hamman BL, et al.
Effect of coronary bypass and valve structure on outcome in isolated valve
replacement for aortic stenosis. Am J Cardiol. 2012;109:1334-40.
19. Tjang YS, van Hees Y, Korfer R, Grobbee DE, van der Heijden GJ. Predictors of
mortality after aortic valve replacement. Eur J Cardiothorac Surg. 2007;32:
469-74.
20. Beach JM,Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al.
Coronary artery disease and outcomes of aortic valve replacement for severe
aortic stenosis. J Am Coll Cardiol. 2013;61:837-48.
21. Nordon I, Brar R, Taylor J, Hinchliffe R, Loftus IM, Thompson MM. Evidence
from cross-sectional imaging indicates abdominal but not thoracic aortic2980 The Journal of Thoracic and Cardiovascular Suraneurysms are local manifestations of a systemic dilating diathesis. J Vasc
Surg. 2009;50:171-6.
22. Jondeau G, Boileau C. Genetics of thoracic aortic aneurysms. Curr Atheroscler
Rep. 2012;14:219-26.
23. Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR.
Natural history of severe atheromatous disease of the thoracic aorta: a
transesophageal echocardiographic study. J Am Coll Cardiol. 1996;27:95-101.
24. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005;
111:816-28.
25. Kieffer E, Chiche L, Baron JF, Godet G, Koskas F, Bahnini A. Coronary and
carotid artery disease in patients with degenerative aneurysm of the descending
thoracic or thoracoabdominal aorta: prevalence and impact on operative
mortality. Ann Vasc Surg. 2002;16:679-84.
26. Marin ML, Hollier LH, Ellozy SH, Spielvogel D, Mitty H, Griepp R, et al.
Endovascular stent graft repair of abdominal and thoracic aortic aneurysms:
a 10-year experience with 817 patients. Ann Surg. 2003;238:586-93.gery c December 2014
TABLE E1. Complete list of parameters analyzed
No CAD (n ¼ 445) CAD (n ¼ 202)
AV (n ¼ 293) AV þ AA (n ¼ 152) AV (n ¼ 189) AV þ AA (n ¼ 13)
TAV
(n ¼ 155)
BAV
(n ¼ 138)
TAV
(n ¼ 31)
BAV
(n ¼ 121)
TAV
(n ¼ 162)
BAV
(n ¼ 27)
TAV
(n ¼ 7)
BAV
(n ¼ 6)
Medical history
Arterial hypertension* 100 (65) 66 (48) 16 (52) 55 (45) 143 (88) 23 (85) 6 (86) 5 (83)
Diabetes mellitus* 22 (14) 19 (14) 0 9 (7) 31 (19) 5 (19) 0 0
Stroke 24 (15) 9 (7) 4 (13) 8 (7) 22 (14) 4 (15) 0 0
Peripheral arterial disease 20 (13) 16 (12) 1 (3) 8 (7) 15 (9) 1 (4) 1 (14) 1 (20)
Relativey with MI/AP 55 (36) 39 (29) 9 (29) 42 (35) 63 (41) 7 (32) 4 (31) 2 (33)
Relativey with stroke 24 (16) 19 (14) 4 (13) 14 (12) 19 (13) 1 (5) 4 (57) 2 (33)
Relativey with VOC 24 (16) 18 (13) 1 (3) 13 (11) 27 (19) 1 (5) 2 (29) 2 (33)
Relativey who died suddenly 12 (8) 18 (14) 2 (7) 9 (8) 39 (26) 7 (32) 3 (43) 1 (17)
Medical treatment
Beta blocker 74 (48) 56 (41) 12 (40) 43 (36) 108 (67) 19 (73) 4 (57) 3 (60)
Acetylsalicylic acid 69 (45) 42 (31) 9 (30) 25 (21) 110 (68) 21 (81) 4 (57) 4 (80)
Other antiplatelet agent 6 (4) 3 (2) 2 (1) 0 11 (7) 3 (12) 0 1 (20)
Anticoagulant 21 (14) 10 (7) 4 (13) 17 (14) 32 (20) 0 0 0
Lipid-lowering agent 79 (51) 48 (35) 6 (20) 36 (30) 127 (78) 21 (81) 4 (57) 1 (20)
Calcium inhibitor 36 (23) 17 (13) 2 (7) 20 (17) 38 (23) 6 (23) 2 (29) 2 (40)
Carvedilol 1 (1) 1 (1) 0 1 (1) 2 (1) 1 (4) 0 0
ACE inhibitor 46 (30) 31 (23) 9 (30) 23 (19) 46 (28) 5 (19) 5 (71) 3 (60)
ARB 29 (19) 15 (11) 9 (30) 16 (13) 25 (15) 5 (19) 2 (17) 1 (20)
Loop diuretics 31 (20) 16 (12) 5 (17) 16 (13) 44 (27) 4 (15) 4 (57) 1 (20)
Thiazide diuretics 36 (23) 12 (8) 5 (17) 14 (12) 27 (17) 7 (27) 2 (29) 0
Oral antidiabetes agent 17 (11) 9 (7) 1 (3) 3 (3) 21 (13) 4 (15) 0 0
Insulin 3 (2) 7 (15) 0 2 (2) 14 (9) 2 (7) 0 0
Long-acting nitrate 7 (5) 2 (1) 1 (3) 1 (1) 34 (21) 3 (12) 0 0
Laboratory finding
Creatininez (mmol/L) 82 (22) 78 (22) 90 (21) 80 (16) 87 (31) 84 (22) 86 (52) 82 (18)
C-reactive proteinx (mg/L) 2 (3) 1 (2) 2 (3) 1 (2) 2 (4) 3 (3) 13 (16) 2 (2)
Triglyceridesk (mmol/L) 1.3 (1.0) 1.0 (0.8) 1.1 (0.9) 1.1 (0.8) 1.1 (0.5) 1.3 (1.5) — —
Cholesterol{ (mmol/L) 4.9 (1.3) 4.9 (1.4) 4.9 (1.4) 5.2 (1.4) 4.1 (0.5) 5.9 (3.4) — —
High-density lipoprotein# (mmol/L) 1.2 (0.6) 1.3 (0.7) 1.3 (0.3) 1.3 (0.5) 1.0 (0.7) 1.4 (0.6) — —
Low-density lipoprotein** (mmol/L) 2.8 (1.3) 3.0 (1.4) 3.2 (0.9) 3.1 (1.3) 2.4 (0.8) 4.1 (3.3) — —
Values are given as frequency (%) or median (interquartile range).CAD, Coronary artery disease; AV, isolated aortic valve pathology; AA, dilatated ascending aorta; TAV, tricuspid
aortic valve; BAV, bicuspid aortic valve; MI, myocardial infarction; AP, angina pectoris; VOC, valvular heart disease; ACE, angiotensin converting enzyme; ARB, angiotensin
receptor blocker. *As defined by ongoing medical treatment. yParent or sibling with diagnosis before age 65 years. zReference value: creatinine,<90 mmol/L. xReference value:
C-reactive protein,<3 mg/L. kReference value: triglycerides, 0.45 to 2.6 mmol/L. {Reference value: cholesterol, 3.9 to 7.8 mmol/L. #Reference value: high-density lipoprotein,
men 0.8 to 2.1 mmol/L and women, 1.0 to 2.7 mmol/L. **Reference value: low-density lipoprotein, 2.0 to 5.3 mmol/L.
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